Form 4: Integra LifeSciences EVP & CHRO Reports Stock Transactions

Integra LifeSciences Holdings Corp's EVP & CHRO, Chantal Veillon-Berteloot, reported the disposition of 3,551 shares of common stock for tax withholding purposes.

Summary

• Chantal Veillon-Berteloot, Executive Vice President & Chief Human Resources Officer of Integra LifeSciences Holdings Corp (IART), reported transactions involving the company's common stock.
• On September 1, 2025, Veillon-Berteloot disposed of 2,139 shares of common stock at a price of $15.13 per share.
• On the same date, September 1, 2025, an additional 1,412 shares of common stock were disposed of at a price of $15.13 per share.
• These dispositions, totaling 3,551 shares, were marked with transaction code 'F,' indicating they were likely for the payment of exercise price or tax liability incident to the vesting of securities.
• Following these transactions, Veillon-Berteloot beneficially owns 27,647 shares of Integra LifeSciences Holdings Corp common stock directly.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction for tax withholding purposes under a Rule 10b5-1 plan, which is a neutral event. It does not indicate any significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-scheduled and non-discretionary sale, which can reduce concerns about insider trading.
• The reporting person retains a significant beneficial ownership of 27,647 shares, aligning her interests with shareholders.

Negatives

• The disposition of shares, even for tax purposes, reduces the direct equity stake of a key executive.

Industry Context

This is a routine insider transaction filing, common across all industries, where executives dispose of shares to cover tax obligations arising from equity compensation vesting. It does not reflect broader industry trends or competitive positioning.

Related Party Transactions

• The disposition of shares by an executive officer (Chantal Veillon-Berteloot) is considered a related party transaction as it involves an insider of the company.

Stakeholder Impact

• Shareholders: The reduction in direct share ownership by a key executive, while for tax purposes, slightly decreases the executive's direct equity alignment with shareholders. However, the executive still holds a significant number of shares.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled disposition of shares for tax purposes by an executive. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's long-term prospects. There is no new information in this filing that would warrant a change in investment recommendation; therefore, a 'hold' recommendation is appropriate, assuming the investor's existing thesis remains unchanged.

Keywords

Integra LifeSciences, IART, Chantal Veillon-Berteloot, Form 4, Insider Trading, Stock Transaction, Executive Compensation, Tax Withholding, Equity Disposition, Rule 10b5-1